This cohort study assesses whether baseline and early therapy circulating tumor DNA measurements differentiate pseudoprogression from true progression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies.
from Cancer via ola Kala on Inoreader http://ift.tt/2nRT3D4
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου